Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...

Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...

Eli Lilly's existing portfolio ... The company also faces pipeline execution risk and commercial execution risk. Like other pharmaceutical companies, Lilly is increasingly exposed to regulatory ...

Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors.

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...